Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab Therapeutics AG into preclinical development for the treatment of lung and gastrointestinal cancers.
Cadherin 17 (CDH17), a member of the cadherin family protein involved in intestinal development and cell adhesion, is recognized as a potential therapeutic target in gastrointestinal (GI) cancers. Its tumor-specific overexpression and limited presence in normal tissues offer a favorable profile for the development of selective, targeted treatments.
Cadherin 17 (CDH17) is a membrane-bound cell adhesion molecule involved in tumor cell proliferation and is selectively overexpressed in several gastrointestinal malignancies, including colorectal cancer, gastric cancer and pancreatic cancer.
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.
Biper Therapeutics SAS has announced bridge financing of €800,000 (US$839,000), ahead of the closure of its series A funding round, to advance its pipeline of drug candidates overstressing pathological cells to treat diseases, including cancer.
Duality Biologics is out-licensing preclinical antibody-drug conjugate (ADC) candidate DB-1324 under an option agreement with GSK plc potentially worth more than $1 billion.
Arbele Ltd. founder and CEO John Luk identified and patented cadherin-17 as a therapeutic cancer target, and the company was founded to develop immunotherapies for gastrointestinal cancers, which are prevalent in Asia Pacific.
Magentiq-Eye Ltd. received U.S. FDA 510(k) clearance for its Magentiq-Colo, an artificial intelligence (AI) gastrointestinal software system that helps detect lesions in real time during colonoscopy procedures. With the rate of colorectal cancer expected to increase steadily through the decade, the company hopes that Magentiq-Colo will offer the gastroenterology community and its patients a significant increase in the adenoma detection rate.
